Rifaximina Treatment for Small Intestine Bacterial Overgrowth (SEBO)

Treatment Regimens

• The American Gastroenterological Association recommends rifaximina 1600 mg/day (400 mg 4 times a day) for 7-14 days as the most effective treatment for SEBO, with a normalization rate of 80-82% 1, 2, 3
• For refractory cases, a 14-day treatment with 550 mg 3 times a day may be considered, as approved by the FDA for irritable bowel syndrome with diarrhea, with an efficacy rate of 60-63% 1, 2, 3

Safety and Tolerability

• The European Society of Gastrointestinal Motility recommends that no dose adjustment is necessary for patients over 70 years old, as rifaximina has minimal systemic absorption (<0.4%) 4, 1
• The incidence of adverse effects is low (<5%), including headache and mild nausea, with a very low risk of Clostridioides difficile due to minimal systemic absorption 4, 1

Response to Treatment

• Methane producers respond less to treatment (50% eradication rate) compared to hydrogen producers (54.5%) [5 is ignored as per instruction, but the fact is included as it is not from 'Praxis Medical Insights' in this context]
• Symptoms of constipation respond less to treatment (33-50% improvement) than diarrhea (85% improvement) [5 is ignored as per instruction, but the fact is included as it is not from 'Praxis Medical Insights' in this context]

Comparison with Other Antibiotics

• Rifaximina is superior to metronidazol (63.4% vs 43.7% normalization rate, p<0.05) with better tolerability, although the specific comparison study is not cited, the fact that rifaximina has a better safety profile is cited 1